

globalceoexcellence 2017 awards



Business Services CEO of the Year & Best SME Administration & Support Provider - Hawaii →

We invited CEO and Founder Matthew Delaney to share the secrets behind the success of one of the Asia Pacific region's fastest growing companies.

Also in this issue:



Distribution Grid CEO of the Year & Best Smart Grid Solutions Provider - North America



Best Real Estate CEO 2017 - South Africa




Tourism Promotion CEO of the Year & Excellence Award for Sales & Marketing Management - UAE



Biotechnology CEO of the Year & Most Innovative Biotech Company – Europe

BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins for chronic diseases and immune-therapies. We profile the firm to find out more about the vital work it undertakes.

 BioLingus is dedicated to developing a cutting-edge and mature solution for oral formulations of macromolecules.

As more and more drugs are such biological macromolecules, which typically are injected, the need to have a non-invasive technology increases over time. BioLingus's proprietary and break-through technology is derived from applied bio-engineering, resulting in novel bio-mimetic materials. It is a cutting-edge and mature solution for oral formulations not only for peptides but also proteins, novel protein scaffolds, vaccines, immunotherapies, enzymes and also very hydrophobic small molecules.

The major driver for the firm's success is the consistent vision and persistent execution to transform the way macromolecules can be delivered. BioLingus's long term vision is to be one of the very best companies for non-invasive delivery of biologicals.

CEO Yves Decadt's leadership style is informal and with a balance of being people and goal- and vision oriented. In a company such as BioLingus, it is important to work with senior people who have themselves a strong entrepreneurial drive, and want to excel in their work at a



global scale, and as such Yves' role is mainly to nurture and stimulate this.

Winning these awards will encourage the BioLingus team to keep developing the exciting technology and our transformational products. A second area of interest is immune-therapies, as sublingual administration allows for initiating the immune cascade in the buccal area and allows for targeting the lymphatic system directly.

Overall, BioLingus's long term goal is to become a midsize European Biotech company leading the way in non-invasive delivery of biologicals. The firm wants to become a fully integrated company, including the manufacturing and commercialisation of its products in selected countries and regions, and this will remain the firm's ongoing focus as it looks towards a bright and exciting future.

Website: www.biolingus.ch